Robot
13.Mar.25 12:06 AM

SentinelOne Exceeds Q4 Expectations, Expects to Surpass $1 Billion in ARR and Revenue this Year

SentinelOne reported strong fourth-quarter earnings, exceeding analyst expectations with revenue of $225.5 million and adjusted earnings of four cents per share. The company's annualized recurring revenue (ARR) increased by 27% year-over-year to $920.1 million, and it expects to surpass $1 billion in ARR and revenue this year.
Robot
13.Mar.25 12:01 AM

Alphabet Stock Rises as Google DeepMind Launches New AI Robotics Platform Gemini Robotics

Alphabet Inc.'s shares rose after Google DeepMind introduced Gemini Robotics and Gemini Robotics-ER, advanced AI robotics platforms built on its Gemini 2.0 model. The new platforms aim to significantly enhance robotic capabilities with improved adaptability, spatial reasoning, and human interaction.
Robot
12.Mar.25 11:48 PM

Cybertruck Takes a Plunge in Ventura Harbor, Highlighting Amphibious Ambitions' Limits

A Tesla Cybertruck owner in California had a rude awakening when their electric vehicle, despite CEO Elon Musk's past claims of its amphibious capabilities, became submerged in Ventura Harbor while attempting to launch a jetski. The incident, which required a multi-agency rescue effort, serves as a stark reminder that the Cybertruck is not a certified boat and should not be treated as such.
Robot
12.Mar.25 11:38 PM

In Line with Estimates, but Outlook Weakens, Leading to After-Hours Stock Decline

American Eagle Outfitters reported fourth-quarter earnings in line with analyst expectations, with comparable sales growth of 3% and a healthy inventory position. However, the company's outlook for the coming year includes a decline in revenue and gross margin, leading to a drop in share price after-hours.
Robot
12.Mar.25 11:35 PM

NIH-Sponsored Trial Finds SIGA's Tecovirimat Ineffective for Clade II Mpox Treatment

An NIH clinical trial found that SIGA Technologies' antiviral drug tecovirimat did not accelerate healing or significantly relieve pain for clade II mpox infections compared to a placebo. Consequently, the trial was halted due to the ineffectiveness identified during interim analyses, aligning with similar findings from another study conducted in the Democratic Republic of the Congo.